Biologic therapy in familial Mediterranean fever

Koga, Tomohiro; Migita, Kiyoshi; Kawakami, Atsushi

doi:10.3109/14397595.2016.1162261

Cited by 31 publications

(22 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, none of these studies were RCTs. In one review, Koga et al reported that 29 FMF patients in various studies had successful results with anti-TNF agents [16]. The efficacy of anti-TNF drugs in the treatment of colchicine-resistant FMF is not yet clear.…”

Section: Discussionmentioning

confidence: 99%

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

et al. 2020

View full text Add to dashboard Cite

İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed.Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3-30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) ≥ 60 ml/min/m 2 , the median proteinuria decreased from 2390 mg/day (range, 1400-7200) to 890 mg/day (range, 120-2750) (p = 0.008). No serious infections were detected, except in one patient.Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR ≥ 60 ml/min/m 2 , but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the longterm effects of these treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Colchicine is currently being used confidently in several diseases due to its anti-inflammatory effect. [31][32] In a recent experimental study which investigated the effects of colchicine, a microtubule-disrupting agent, on skeletal muscle ischemic injury in rats, the authors suggested that 1mg/kg colchicine significantly decreased levels of malondialdehyde, TNF-α, and IL-1β and increased superoxide dismutase in ischemic tissues. 33 In addition, at higher doses colchicine exerts various other inflammatory effects including suppression of phospholipase A2 activation, lysosomal enzyme release, and phagocytosis.…”

Section: Discussionmentioning

confidence: 99%

The effect of colchicine on alveolar bone loss in ligature-induced periodontitis

et al. 2019

View full text Add to dashboard Cite

Colchicine is widely used in the treatment of several inflammatory diseases due to its anti-inflammatory effect, but effects on bone metabolism are unclear. The aim of this study was to evaluate the effects of systemically-administered colchicine on healthy periodontium and experimentally-induced periodontitis. In total, 42 male Wistar rats were included in this study. A non-ligated group constituting the negative control group (Control, C, n = 6) and a ligature-only group forming the positive control group (LO, n = 12) were created separately. Twelve rats were treated with 0.4 mg/kg colchicine and another 12 with 1 mg/kg colchicine. In the colchicine-administered groups, right mandibles constituted the ligated groups (1 mgC-L or 0.4 mgC-L) and left mandibles formed the corresponding non-ligated controls (1mgC or 0.4mgC). Silk ligatures were placed at the gingival margin of the lower first molars. The animals were euthanized at different time-points of healing (11 or 30 days). Alveolar bone loss was clinically measured and TRAP+ osteoclasts, osteoblastic activity, and MMP-1 expression were examined histologically. There was no increase in alveolar bone loss with either colchicine dose in healthy periodontium (p > 0.05) and the highest level of alveolar bone loss, TRAP+ osteoclast number, and MMP-1 expression were measured in the LO group (p < 0.05). The 0.4 mgC-L group showed less alveolar bone loss at 11 days (p < 0.05), but greater loss at 30 days. The 1 mgC-L group showed higher osteoblast number than the other ligated groups (p < 0.05) at both time-points. In summary, colchicine did not increase alveolar bone loss in healthy periodontium and also may tend to reduce periodontitis progression. However, further extensive study is necessary to understand the mechanism of colchicine action on alveolar bone loss in periodontitis.

show abstract

“…Chronische destruktive (Hüft-)Arthritiden [86,87] sowie HLA-B27-negative seronegative Spondyloarthritis [88,89] sind als gesondert zu betrachtende Manifestationen des FMF anzusehen, die sich häufig durch Colchicin nicht ausreichend therapieren lassen. In diesen Fällen kann der Einsatz von nichtsteroidalen Antiphlogistika (NSAR), lokalen Glukokortikoiden, Methotrexat oder auch TNF-Blockern sinnvoll sein [3,90]. Kontrollierte Studien liegen hierzu aber nicht vor.…”

Section: Therapieempfehlungunclassified